经颅电刺激与术后谵妄:一项随机临床试验
MODEST试验为双盲、假刺激对照随机临床试验,在德国格赖夫斯瓦尔德大学医学中心自2024年2月8日至2025年1月15日纳入225例65岁及以上择期手术患者,排除有神经或精神疾病史或使用中枢神经系统活性药物者。患者术后在麻醉后监护室随机接受α-tACS(靶向突显网络)、tDCS(靶向前顶叶网络,20分钟、2 mA)或假刺激。主要终点病房内术后谵妄发生率在tACS组11.5% vs 假刺激组9.2%(OR 1.60,95%CI 0.47-5.46;P=0.45),tDCS组14.3% vs 假刺激组(OR 1.51,95%CI 0.49-4.68;P=0.47),均无显著差异;麻醉后监护室谵妄发生率亦无显著差异。预设亚组分析显示手术时长可能影响tACS对麻醉后监护室谵妄的效应(OR 0.15,95%CI 0.02-0.97;P=0.046),手术3至5小时者tACS组绝对风险差为-26.6%至-46.5%。不良事件评分组间无差异(发生率比2.3,95%CI 0.8-6.5),未报告严重不良事件。
要点
- 在225例65岁及以上择期手术后患者中,术后tACS或tDCS与假刺激相比,病房内术后谵妄发生率无显著差异(tACS 11.5% vs 假刺激9.2%,OR 1.60,95%CI 0.47-5.46;tDCS 14.3% vs 假刺激,OR 1.51,95%CI 0.49-4.68)。
- 麻醉后监护室谵妄发生率亦无显著组间差异(tACS 14.6% vs 假刺激21.7%,OR 0.95,95%CI 0.38-2.36;tDCS 21.4% vs 假刺激,OR 0.91,95%CI 0.36-2.30)。
- 预设亚组分析提示手术时长可能调节tACS对麻醉后监护室谵妄的效应(OR 0.15,95%CI 0.02-0.97;P=0.046),手术3至5小时者tACS组绝对风险差为-26.6%至-46.5%。
- 谵妄严重程度、运动亚型及术后疼痛的进一步次要分析未显示刺激组间任何实质性差异。
- 不良事件评分组间无差异(发生率比2.3,95%CI 0.8-6.5),未报告严重不良事件。
适用人群与场景
- 65岁及以上、计划接受择期手术的患者。
- 排除标准:任何神经或精神疾病史,或使用中枢神经系统活性药物。
- 研究在德国格赖夫斯瓦尔德大学医学中心开展,干预在重大择期手术后麻醉后监护室实施。
处置流程与药物剂量
- α-tACS靶向突显网络、tDCS靶向前顶叶网络或假刺激,于重大择期手术后麻醉后监护室实施,剂量为20分钟、2 mA。
研究设计与关键结果
- 研究类型:双盲、假刺激对照随机临床试验(MODEST),在德国格赖夫斯瓦尔德大学医学中心开展,2024年2月8日至2025年1月15日纳入225例患者(平均[SD]年龄73.0[6.0]岁;59.6%[134]男性),随机分为tACS组(n=68)、tDCS组(n=83)或假刺激组(n=74)。
- 主要终点:病房内术后谵妄发生率(tACS vs 假刺激):tACS组11.5%(6/52)vs 假刺激组9.2%(6/65),OR 1.60(95%CI 0.47-5.46),P=0.45。
- 次要终点:病房内术后谵妄发生率(tDCS vs 假刺激):tDCS组14.3%(9/63)vs 假刺激组9.2%(6/65),OR 1.51(95%CI 0.49-4.68),P=0.47。
- 麻醉后监护室术后谵妄发生率:tACS组14.6%(7/48)vs 假刺激组21.7%(13/60),OR 0.95(95%CI 0.38-2.36),P=0.91;tDCS组21.4%(12/56)vs 假刺激组21.7%(13/60),OR 0.91(95%CI 0.36-2.30),P=0.83。
- 预设亚组分析:手术时长对麻醉后监护室术后谵妄发生率的调节作用OR 0.15(95%CI 0.02-0.97),P=0.046;手术时长3至5小时者tACS组与假刺激组相比术后谵妄绝对风险差为-26.6%至-46.5%。
- 谵妄严重程度、运动亚型及疼痛水平的进一步次要分析未显示刺激组间任何实质性差异。
- 不良事件评分组间无差异(发生率比2.3,95%CI 0.8-6.5),未报告严重不良事件。
证据类型、等级与局限
- 证据类型:双盲、假刺激对照随机临床试验。
- 试验注册:德国临床试验注册处DRKS00033703。
- 局限:未来研究须检验对脆弱人群的具体效应、考察tES调制术后谵妄的最佳时机、并探究个体化tES参数的价值。
对床旁实践的改变
- 作者认为,术后tES对术后谵妄发生率没有一致效应的证据,但提示顶叶α振荡增强对手术时间较长的患者有益。
- 作者建议未来研究须检验对脆弱人群的具体效应、考察tES调制术后谵妄的最佳时机、并探究个体化tES参数的价值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Postoperative delirium (POD) occurs as a significant complication after elective surgery.
OBJECTIVE: To investigate the modulation of delirium incidence by transcranial electric stimulation (tES).
DESIGN, SETTING, AND PARTICIPANTS: A double-blind, sham-controlled randomized clinical trial (Modulating Delirium Through Stimulation [MODEST]) was conducted at University Medicine Greifswald, Germany, from February 8, 2024, to January 15, 2025. Patients were aged 65 years or older who were scheduled to undergo elective surgery. Exclusion criteria were any history of neurological or psychiatric disease, or intake of central nervous system-active medication. Data were analyzed from June 10, 2025, to June 5, 2026.
INTERVENTION: α-Transcranial alternating current stimulation (tACS) of the salience network, transcranial direct current stimulation (tDCS) of the frontoparietal network (dosing: 20 minutes, 2 mA), or sham, in the postanesthesia care unit (PACU) after major elective surgery.
MAIN OUTCOMES AND MEASURES: The primary outcome was POD incidence in the ward during 1 of up to 5 postoperative days for the comparison of tACS vs the sham group. The secondary outcomes included POD in the ward for the comparison of tDCS vs sham group, POD in PACU, POD severity and motor type, and postoperative pain. Prespecified subgroup analyses opted to test the dependence of POD incidence on age, sex, duration, and type of surgery, baseline cognitive function, and preoperative pain levels.
RESULTS: A total of 225 patients (mean [SD] age, 73.0 [6.0] years; 59.6% [134] male) were randomly assigned to tACS (n = 68), tDCS (n = 83), or sham stimulation (n = 74). No substantial between group differences were observed for POD incidence in ward (tACS, 11.5% [6 of 52]; tDCS, 14.3% [9 of 63]; sham, 9.2% [6 of 65]; tACS vs sham: odds ratio [OR], 1.60 [95% CI, 0.47-5.46]; P = .45; tDCS vs sham: OR, 1.51 [95% CI, 0.49-4.68]; P = .47) or in PACU (tACS, 14.6% [7 of 48]; tDCS, 21.4% [12 of 56]; sham, 21.7% [13 of 60]; tACS vs sham: OR, 0.95 [95% CI, 0.38-2.36]; P = .91; tDCS vs sham: OR, 0.91 [95% CI, 0.36-2.30]; P = .83). Further secondary analyses of POD severity and motor type, and modulation of pain levels, did not show any substantial difference between stimulation groups. Prespecified subgroup analyses revealed different modulation of POD incidence in PACU depending on duration of surgery (OR, 0.15 [95% CI, 0.02-0.97]; P = .046), indicating that tACS may reduce POD incidence for patients with longer surgery (absolute risk difference for POD in the tACS compared with the sham group, for a surgical duration of 3 to 5 hours of -26.6% to -46.5%). Ratings of adverse events did not differ between groups (incidence rate ratio, 2.3 [95% CI, 0.8-6.5]), and no serious adverse events were reported.
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of tES for POD, there was no evidence for a uniform effect of postoperative tES on the incidence of POD, but it suggested a benefit of parietal α oscillatory enhancement for patients with longer surgery. Future research has to test the specific effect on vulnerable groups, examine the optimal timing for tES application to modulate POD, and investigate the value of personalizing tES parameters.
TRIAL REGISTRATION: German Clinical Trials Register: DRKS00033703.
参考来源
- Antonenko D, Bublitz V, Leroy S, et al. Transcranial Electrical Stimulation and Delirium Among Postoperative Patients: A Randomized Clinical Trial. JAMA Netw Open. 2026. PMID: 42611517. doi:10.1001/jamanetworkopen.2026.28284
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。